Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Angelman Trial Failure And Cost-Cut Plan
Phase 3negativeNegative
AI Analysis
Summary
Ultragenyx Pharmaceutical experienced a 40.3% stock decline following failure of its Angelman syndrome trial and announcement of a cost-cutting plan.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Angelman trial failure
Importance:8/10
Sentiment:
-0.95
trial failurestock declinecost cutsrare diseaseAngelman syndrome
Related Companies
Read the original article
Published by yahoo_finance on September 5, 2026 1:08 AM